{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:18:25Z","timestamp":1777385905083,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Am J Rhinol\ufffdAllergy"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Guidelines from throughout the world recommend intranasal corticosteroids (INSs) as first-line treatment for most patients with moderate to severe allergic rhinitis. In general, limited comparative studies between different INSs have not indicated that one particular steroid moiety is more effective than another in controlling symptoms of allergic rhinitis. However, there are numerous formulations available with different ingredients that may influence a patient's adherence to treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This article looks at topical features with these agents, specifically, formulations, vehicles (aqueous vs aerosol), and side effects such as epistaxis and nasal septal perforation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Topical side effects are minimal with INSs with the exception of epistaxis. There are major differences in formulations, volumes, and vehicles between INSs, which could affect adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Physicians need to be aware of the different INS attributes to try to match patients\u2019 preferences in order to achieve better adherence and improve outcomes in sufferers of allergic rhinitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2500\/ajra.2013.27.3949","type":"journal-article","created":{"date-parts":[[2013,11,22]],"date-time":"2013-11-22T23:54:05Z","timestamp":1385164445000},"page":"510-513","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["Intranasal Corticosteroids Topical Characteristics: Side Effects, Formulation, and Volume"],"prefix":"10.1177","volume":"27","author":[{"given":"David A.","family":"Petty","sequence":"first","affiliation":[{"name":"Departments of Pediatrics and Medicine, Division of Clinical Immunology and Allergy, University of Tennessee Health Science Center, Memphis, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Blaiss","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and Medicine, Division of Clinical Immunology and Allergy, University of Tennessee Health Science Center, Memphis, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,11,1]]},"reference":[{"key":"bibr1-ajra.2013.27.3949","doi-asserted-by":"publisher","DOI":"10.2500\/ajr.2007.21.2896"},{"key":"bibr2-ajra.2013.27.3949","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)63030-X"},{"key":"bibr3-ajra.2013.27.3949","doi-asserted-by":"publisher","DOI":"10.1177\/019459989811800514"},{"key":"bibr4-ajra.2013.27.3949","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1986.tb00298.x"},{"key":"bibr5-ajra.2013.27.3949","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.16.1458.33692"},{"key":"bibr6-ajra.2013.27.3949","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2011.32.3438"},{"key":"bibr7-ajra.2013.27.3949","doi-asserted-by":"publisher","DOI":"10.1177\/014556130808700812"},{"key":"bibr8-ajra.2013.27.3949","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(93)90274-J"},{"key":"bibr9-ajra.2013.27.3949","first-page":"87","volume":"38","author":"Kyrmizakis DE","year":"2000","journal-title":"Rhinology"},{"key":"bibr10-ajra.2013.27.3949","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60373-0"},{"key":"bibr11-ajra.2013.27.3949","first-page":"128","volume":"36","author":"Cervin A","year":"1998","journal-title":"Rhinology"},{"key":"bibr12-ajra.2013.27.3949","first-page":"287","volume":"19","author":"Deepak D","year":"2001","journal-title":"Asian Pac J Allergy Immunol"},{"key":"bibr13-ajra.2013.27.3949","unstructured":"Data on File, Sunovion Pharmaceuticals 2 week SAR trial (602 trial, NCT00807053) Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010\/M1-602). Clinicaltrials.gov number 000807053."},{"key":"bibr14-ajra.2013.27.3949","unstructured":"Data on file, Sunovion Pharmaceuticals 2 week SAR trial (634 trial, NCT00790023). Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis. Clinicaltrials.gov number 00790023."},{"key":"bibr15-ajra.2013.27.3949","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2012.33.3522"},{"key":"bibr16-ajra.2013.27.3949","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2012.33.3571"},{"key":"bibr17-ajra.2013.27.3949","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2011.32.3473"},{"key":"bibr18-ajra.2013.27.3949","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60854-X"},{"key":"bibr19-ajra.2013.27.3949","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2007.28.2993"},{"key":"bibr20-ajra.2013.27.3949","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61393-2"},{"key":"bibr21-ajra.2013.27.3949","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2012.33.3565"},{"key":"bibr22-ajra.2013.27.3949","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2006.27.2852"}],"container-title":["American Journal of Rhinology &amp; Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2500\/ajra.2013.27.3949","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.2500\/ajra.2013.27.3949","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2500\/ajra.2013.27.3949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:34:24Z","timestamp":1777368864000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.2500\/ajra.2013.27.3949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.2500\/ajra.2013.27.3949"],"URL":"https:\/\/doi.org\/10.2500\/ajra.2013.27.3949","relation":{},"ISSN":["1945-8924","1945-8932"],"issn-type":[{"value":"1945-8924","type":"print"},{"value":"1945-8932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}